{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:59:33Z","timestamp":1791910773149,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s13555-024-01291-0","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T16:03:44Z","timestamp":1730563424000},"page":"3211-3227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Equity and Outcome Events in Hidradenitis Suppurativa: Exploring Effect Modifiers Associated with Diagnostic Delay in the Real World"],"prefix":"10.1007","volume":"14","author":[{"given":"Nicole","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-2902","authenticated-orcid":false,"given":"Isabel","family":"Truman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Adlard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"issue":"1","key":"1291_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.","journal-title":"Nat Rev Dis Primers"},{"issue":"1062","key":"1291_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/postgradmedj-2013-131994","volume":"90","author":"DN Dufour","year":"2014","unstructured":"Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90(1062):216\u201321 (quiz 20).","journal-title":"Postgrad Med J"},{"issue":"9","key":"1291_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamadermatol.2014.691","volume":"150","author":"JS Kirby","year":"2014","unstructured":"Kirby JS, Miller JJ, Adams DR, Leslie D. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. 2014;150(9):937\u201344.","journal-title":"JAMA Dermatol"},{"issue":"5 Suppl 1","key":"1291_CR4","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","volume":"73","author":"GB Jemec","year":"2015","unstructured":"Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4-7.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1291_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","volume":"138","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. J Investig Dermatol. 2018;138(1):52\u20137.","journal-title":"J Investig Dermatol"},{"issue":"8","key":"1291_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","volume":"157","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O\u2019Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa. JAMA Dermatol. 2021;157(8):924.","journal-title":"JAMA Dermatol"},{"key":"1291_CR7","doi-asserted-by":"publisher","unstructured":"Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation\u2014systematic review and meta-analysis. Biomed Dermatol. 2020;4(2). https:\/\/doi.org\/10.1186\/s41702-019-0052-0.","DOI":"10.1186\/s41702-019-0052-0"},{"issue":"8","key":"1291_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760\u20134.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1291_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/1203475420972348","volume":"25","author":"M Sachdeva","year":"2021","unstructured":"Sachdeva M, Shah M, Alavi A. Race-specific prevalence of hidradenitis suppurativa. J Cutan Med Surg. 2021;25(2):177\u201387.","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"1291_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1291_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/01.ASW.0000465674.34810.e9","volume":"28","author":"SC Wang","year":"2015","unstructured":"Wang SC, Wang SC, Sibbald RG, Alhusayen R, Bashash M, Alavi A. Hidradenitis suppurativa: a frequently missed diagnosis, part 1: a review of pathogenesis, associations, and clinical features. Adv Skin Wound Care. 2015;28(7):325\u201332 (quiz 33-4).","journal-title":"Adv Skin Wound Care"},{"issue":"5","key":"1291_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jid.2020.10.014","volume":"141","author":"JS Kirby","year":"2021","unstructured":"Kirby JS. Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema. J Investig Dermatol. 2021;141(5):1136\u20138.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"1291_CR13","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/bjd.18818","volume":"182","author":"N Shukla","year":"2020","unstructured":"Shukla N, Paul M, Halley M, et al. Identifying barriers to care and research in hidradenitis suppurativa: findings from a patient engagement event. Br J Dermatol. 2020;182(6):1490\u20132.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1291_CR14","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jid.2019.03.268","volume":"139","author":"B Kromenacker","year":"2019","unstructured":"Kromenacker B, Maarouf M, Hendricks A, Hsiao J, Shi V. 192 Diagnostic delay in hidradenitis suppurativa. J Investig Dermatol. 2019;139(5):S33.","journal-title":"J Investig Dermatol"},{"key":"1291_CR15","doi-asserted-by":"crossref","unstructured":"Barnes LA, Shukla N, Paul M, de Vere Hunt I, Halley MC, Linos E, et al. Patient perspectives of health system barriers to accessing care for hidradenitis suppurativa: a qualitative study. JAMA Dermatol. 2023.","DOI":"10.1001\/jamadermatol.2023.0486"},{"issue":"6","key":"1291_CR16","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/bjd.14038","volume":"173","author":"DM Saunte","year":"2015","unstructured":"Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1291_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"key":"1291_CR18","unstructured":"Kirby JS, Hsiao JL, Muscianisi E, Nguyen ES, Hi VY. The hidradenitis suppurativa journey: a survey of US patients and providers. 11th EHSF Conference 2022."},{"issue":"5","key":"1291_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236(5):421\u201330.","journal-title":"Dermatology"},{"issue":"7","key":"1291_CR20","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1080\/09546634.2022.2089336","volume":"33","author":"DR De","year":"2022","unstructured":"De DR, Shih T, Fixsen D, Brooks B, Hsiao JL, Shi VY. Biologic use in hidradenitis suppurativa: patient perspectives and barriers. J Dermatolog Treat. 2022;33(7):3060\u20132.","journal-title":"J Dermatolog Treat"},{"key":"1291_CR21","unstructured":"Bewley A, Malcolm B, Shah P. The primary care management of hidradenitis suppurativa in the UK: an evaluation of patient pathways and healthcare resource use using The Health Improvement Network database. Br J Dermatol 2016;(175 Suppl S1):9\u201315."},{"issue":"1","key":"1291_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1684\/ejd.2018.3478","volume":"29","author":"H Clerc","year":"2019","unstructured":"Clerc H, Tavernier E, Giraudeau B, et al. Understanding the long diagnostic delay for hidradenitis suppurativa: a national survey among French general practitioners. Eur J Dermatol. 2019;29(1):97\u20139.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"1291_CR23","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.1111\/ajd.13672","volume":"62","author":"JW Rick","year":"2021","unstructured":"Rick JW, Thompson AM, Fernandez JM, et al. Misdiagnoses and barriers to care in hidradenitis suppurativa: a patient survey. Australas J Dermatol. 2021;62(4):e592\u20134.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"1291_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/bjd.20523","volume":"185","author":"L Howells","year":"2021","unstructured":"Howells L, Lancaster N, McPhee M, et al. Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review. Br J Dermatol. 2021;185(5):921\u201334.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1291_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","volume":"13","author":"E Aromataris","year":"2015","unstructured":"Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13(3):132\u201340.","journal-title":"Int J Evid Based Healthc"},{"issue":"11","key":"1291_CR26","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1291_CR27","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1291_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"1291_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type\u00a02 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes Targets Therapy. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes Targets Therapy"},{"key":"1291_CR30","unstructured":"European Pharmaceutical Market Research Association (EPhMRA). Code of Conduct 2022. https:\/\/www.ephmra.org\/sites\/default\/files\/2022-08\/EPHMRA%202022%20Code%20of%20Conduct.pdf. Accessed 5 Aug 2024"},{"key":"1291_CR31","unstructured":"Health Information Technology (HITECH). Health Information Technology Act 2009. https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf. Accessed 5 Aug 2024"},{"issue":"2","key":"1291_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/hex.13410","volume":"25","author":"A Robinson","year":"2022","unstructured":"Robinson A, Elarbi M, Todd A, Husband A. A qualitative exploration of the barriers and facilitators affecting ethnic minority patient groups when accessing medicine review services: perspectives of healthcare professionals. Health Expect. 2022;25(2):628\u201338.","journal-title":"Health Expect"},{"key":"1291_CR33","unstructured":"Kokolakis G, Guillem P, Vilarrasa E, et al. Revealing patient perspectives on hidradenitis suppurativa according to racial background: results from a global study. In: The American Academy of Dermatology Annual Meeting. The American Academy of Dermatology Annual Meeting, 2024."},{"key":"1291_CR34","doi-asserted-by":"crossref","unstructured":"Ulschmid C, Serrano L, Wu R, Roth GM, Sokumbi O. African American race is a risk factor for severe hidradenitis suppurativa. Int J Dermatol.  2023;62(5):657\u201363.","DOI":"10.1111\/ijd.16428"},{"issue":"9","key":"1291_CR35","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1001\/jamadermatol.2021.2999","volume":"157","author":"E Edigin","year":"2021","unstructured":"Edigin E, Kaul S, Eseaton PO, Albrecht J. Racial and ethnic distribution of patients hospitalized with hidradenitis suppurativa, 2008\u20132018. JAMA Dermatol. 2021;157(9):1125.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1291_CR36","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamadermatol.2020.1047","volume":"156","author":"A-HR J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen A-HR, Aarestrup J, Baker JL, Thomsen SF. Association of birth weight, childhood body mass index, and height with risk of hidradenitis suppurativa. JAMA Dermatol. 2020;156(7):746.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1291_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jdv.14599","volume":"32","author":"P Theut Riis","year":"2018","unstructured":"Theut Riis P, Saunte DM, Benhadou F, et al. Low and high body mass index in hidradenitis suppurativa patients-different subtypes? J Eur Acad Dermatol Venereol. 2018;32(2):307\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1291_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.603281","volume":"8","author":"JW Frew","year":"2021","unstructured":"Frew JW, Singh N, Jiang CS, Vaughan R, Krueger JG. The impact of body mass index upon the efficacy of adalimumab in hidradenitis suppurativa. Front Med (Lausanne). 2021;8:603281.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"1291_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000018126","volume":"198","author":"A K\u00f6nig","year":"1999","unstructured":"K\u00f6nig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology. 1999;198(3):261\u20134.","journal-title":"Dermatology"},{"key":"1291_CR40","doi-asserted-by":"crossref","unstructured":"Garg A, Papagermanos V, Midura M, Strunk A. Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol. 2018;178(3):709\u201314.","DOI":"10.1111\/bjd.15939"},{"issue":"5","key":"1291_CR41","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/bjd.15234","volume":"176","author":"L Naldi","year":"2017","unstructured":"Naldi L, Cazzaniga S, Di Mercurio M, Grossi E, Addis A. Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry. Br J Dermatol. 2017;176(5):1331\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1291_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2217\/imt-2018-0090","volume":"11","author":"K W\u0142odarek","year":"2019","unstructured":"W\u0142odarek K, Ponikowska M, Matusiak \u0141, Szepietowski JC. Biologics for hidradenitis suppurativa: an update. Immunotherapy. 2019;11(1):45\u201359.","journal-title":"Immunotherapy"},{"issue":"6","key":"1291_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/14712598.2020.1732918","volume":"20","author":"M Rosales Santillan","year":"2020","unstructured":"Rosales Santillan M, Morss PC, Porter ML, Kimball AB. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2020;20(6):621\u201333.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"1291_CR44","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40257-024-00871-2","volume":"25","author":"CB Dagenet","year":"2024","unstructured":"Dagenet CB, Atluri S, Ma E, et al. Adherence to hidradenitis suppurativa treatment. Am J Clin Dermatol. 2024;25(4):585\u201394.","journal-title":"Am J Clin Dermatol"},{"key":"1291_CR45","doi-asserted-by":"crossref","unstructured":"Moltrasio C, Tricarico PM, Romagnuolo M, Marzano AV, Crovella S. Hidradenitis suppurativa: a perspective on genetic factors involved in the disease. Biomedicines. 2022;10(8):2039.","DOI":"10.3390\/biomedicines10082039"},{"issue":"9","key":"1291_CR46","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/jamadermatol.2023.2217","volume":"159","author":"Q Sun","year":"2023","unstructured":"Sun Q, Broadaway KA, Edmiston SN, et al. Genetic variants associated with hidradenitis suppurativa. JAMA Dermatol. 2023;159(9):930\u20138.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1291_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000503605","volume":"237","author":"J Aleksi","year":"2021","unstructured":"Aleksi J, Michelle V. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237(1):81\u201396.","journal-title":"Dermatology"},{"issue":"6","key":"1291_CR48","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjd.19435","volume":"183","author":"JR Ingram","year":"2020","unstructured":"Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1291_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000505292","volume":"236","author":"F Benhadou","year":"2020","unstructured":"Benhadou F, Villani AP, Guillem P. Which factors determine affected sites in hidradenitis suppurativa? Dermatology. 2020;236(1):15\u201320.","journal-title":"Dermatology"},{"issue":"5","key":"1291_CR50","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1111\/ced.13861","volume":"44","author":"L Bianchi","year":"2019","unstructured":"Bianchi L, Caposiena Caro RD, Ganzetti G, et al. Sex-related differences of clinical features in hidradenitis suppurativa: analysis of an Italian-based cohort. Clin Exp Dermatol. 2019;44(5):e177\u201380.","journal-title":"Clin Exp Dermatol"},{"issue":"5Part B","key":"1291_CR51","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ijwd.2021.07.003","volume":"7","author":"T Shih","year":"2021","unstructured":"Shih T, Seivright JR, McKenzie SA, et al. Gender differences in hidradenitis suppurativa characteristics: a retrospective cohort analysis. Int J Womens Dermatol. 2021;7(5Part B):672\u20134.","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"1291_CR52","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2014.04.001","volume":"71","author":"AM Schrader","year":"2014","unstructured":"Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71(3):460\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1291_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaad.2009.02.013","volume":"61","author":"F Canoui-Poitrine","year":"2009","unstructured":"Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol. 2009;61(1):51\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1291_CR54","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jdv.18163","volume":"36","author":"JR Ingram","year":"2022","unstructured":"Ingram JR, Bettoli V, Espy JI, et al. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. J Eur Acad Dermatol Venereol. 2022;36(9):1597\u2013605.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1291_CR55","unstructured":"Kokolakis G, Guillem P, Vilarrasa E, et al. The impact on pain and mental health in patients with hidradenitis suppurativa: Results from the HS Uncovered global patient survey. In: 13th CONFERENCE of the European Hidradenitis Suppurativa Foundation e V2024."},{"key":"1291_CR56","unstructured":"Kokolakis G, Guillem P, Vilarrasa E, et al. HS Uncovered: Results from a global survey revealing patient perspective in hidradenitis suppurativa. In: Symposium on Hidradenitis Suppurativa Advances 2023."},{"key":"1291_CR57","doi-asserted-by":"crossref","unstructured":"Kohorst JJ, Ghanavatian S, Davis MDP, Weaver AL, Schleck CD, Swanson DL. Long-term risk of death in patients with hidradenitis suppurativa. Int J Dermatol. 2023;62(5):631\u20136.","DOI":"10.1111\/ijd.16409"},{"issue":"9","key":"1291_CR58","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304.","journal-title":"Ann Intern Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01291-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01291-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01291-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:24:37Z","timestamp":1732857877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01291-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01291-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicole Murray was an employee of Novartis Corporate Center (NOCC), Dublin, Ireland during the development of this work. Isabel Truman and Gary Milligan are employed by Adelphi Real World, Bollington, UK. Himanshu Modi is an employee of Novartis Corporate Center (NOCC), Hyderabad, India. Nicholas Adlard is an employee of Novartis Pharma AG, Basel, Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The survey was performed in compliance with the European Pharmaceutical Market Research Association (EphMRA) [] and in full accordance with the US Health Insurance Portability and Accountability Act (HIPAA) 1996 [] and the Helsinki Declaration of 1964 and its later amendments. Ethical approval was granted by the Western Copernicus Group Institutional Review Board (WCG-IRB, approval number AG8836). Using a checkbox, patients provided informed consent to take part in the survey. Data were collected in such a way that patients and physicians could not be identified directly.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}